분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-07-22 23:33:51 , Hit : 1647
 Gilead Drug Combination Cures Hepatitis C in HIV Patients

By Marie French  Jul 20, 2014 11:10 PM GMT+0900  


Aug 1Sep 1Oct 1Nov 1Dec 1Jan 1Feb 1Mar 1Apr 1May 1Jun 1Jul 160.0070.0080.0090.00* Price chart for GILEAD SCIENCES INC. Click flags for important stories. GILD:US89.420.56 0.62%


Gilead Sciences Inc.’s (GILD) Solvadi, controversial because of its price, helps cure hepatitis C in people with HIV, according to researchers who say the drug has the potential to limit a top cause of death in these patients.

In a study of 223 HIV-infected patients, Solvadi combined with ribavirin cleared the most common U.S. strain of hepatitis C in 76 percent of newly treated patients over 24 weeks. Only seven participants stopped treatment because of side effects and there were no adverse effects on HIV treatment, according to a report in the Journal of the American Medical Association.

Complications from hepatitis C are the leading cause of death for those with HIV, according to the research. In the past, treatment for 7 million patents co-infected with the viruses globally have been limited because older hepatitis C regimens that include interferon interact badly with HIV drugs, with more anemia, fatigue and depression, researchers said.

This is “the first clinical trial to demonstrate that we can cure hepatitis C in patients with HIV co-infection without the use of interferon,” said Mark Sulkowski, the study author and medical director of the John Hopkins Infectious Disease Center for Viral Hepatitis in Baltimore. “It represents a transformative step in our approach to this therapeutic area.”

The hepatitis C virus can lead to chronic liver disease, liver scarring and cancer, sometimes requiring a transplant.

“We can achieve excellent effects with co-infection in a manner we’ve achieved with mono-infections,” said Raymond Chung, a doctor at Massachusetts General Hospital who was not involved with this study. “Now that we’re in the effective conversion of HIV to a chronic disease, the new opportunist if you will is complications from hep-C.”

Step Forward

While these results represent a step forward, the cost of the course of treatment could be prohibitive for many patients, said Michael Saag, an AIDS researcher at the University of Alabama in Birmingham in an e-mail. He wrote an editorial accompanying the research about the challenges to access.

“The patients and providers who have to file countless forms, often multiple times, simply to obtain approval for the drugs and the payers, including many government systems around the world, are heavily burdened by the pricing,” Saag said in an e-mail. “I don’t think the new drugs at the current prices are affordable. It is a shame.”

Other drugs are also expected to become available for hepatitis C in the next six months and may drive those costs down, Chung said. AbbVie and Merck & Co. (MRK) are among companies with drugs for hepatitis C in phase II trials, according to a Bloomberg Industries report. Olysio, a Johnson & Johnson (JNJ) hepatitis C pill, was cleared last November by the Food and Drug Administration. It isn’t recommended for patients with HIV, according to information on the FDA’s website.

$94,500 Cost

Even with new drugs entering the market, Saag said he was skeptical about pharmaceutical companies dropping the price. The 12-week course of treatment would be $94,500 and the 24-week course $189,000, according to Saag’s editorial. The high cost of Sovaldi has come under scrutiny from U.S. lawmakers and U.K. regulators.

“The pricing of drugs is a good example of where a ‘free market’ might exist, but in my experience never does,” Saag said. “I’m not holding my breath.”

Michele Rest, a spokeswoman for Gilead, cited the “clear need for HVC treatment regimens that are more effective and safer” for those co-infected with HIV.’’

The drug combination was approved for use by HIV-positive people with types 2 and 3 hepatitis C virus by the U.S. Food and Drug Administration in December. For those with type 1, the recommended course of treatment includes interferon, which changes the immune system’s responses and can interact badly with HIV-controlling drugs, Chung said in a telephone interview.

To contact the reporter on this story: Marie French in New York at mfrench25@bloomberg.net

To contact the editors responsible for this story: Reg Gale at rgale5@bloomberg.net Angela Zimm







927   치료가 어려운 C형 간염에 대한 새로운 경구 병용 요법  이성욱 2014/08/01 1680
926   배양된 사람 세포에서 HIV를 제거하는데 처음으로 성공  이성욱 2014/07/31 1467
925   새로운 약물저항성 발달 메커니즘: RNA 간섭  이성욱 2014/07/31 1465
924   물려받은 각인 유전자의 영향 하에 있는 딸의 사춘기  이성욱 2014/07/29 1645
923   노화 관련 질환 예방을 위한 새로운 전략  이성욱 2014/07/28 1460
922   에이즈 치료의 새 희망 - 암 치료를 받으니 HIV 바이러스가 사라졌네?  이성욱 2014/07/24 1607
  Gilead Drug Combination Cures Hepatitis C in HIV Patients  이성욱 2014/07/22 1647
920   유전자요법을 이용한 생물학적 심박조율기  이성욱 2014/07/18 1861
919   박테리아와 바이러스에 존재하는 나노 바이오모터(biomotor)  이성욱 2014/07/18 1680
918   항생제 내성을 증가시키는 CRISPR 시스템  이성욱 2014/07/18 1989
917   사라진 HIV 감염 완치의 희망: `미시시피 아기` HIV 양성반응  이성욱 2014/07/17 2014
916   간암을 초래할 수 있는 돌연변이  이성욱 2014/07/11 1470
915   숙주의 세포에 숨기 위하여 가짜 단백질을 이용하는 바이러스  이성욱 2014/07/11 1777
914   Sleeping Beauty Transposon 시스템을 이용한 진균 감염에 대한 면역능 회복  이성욱 2014/07/11 1994
913   STAP세포 논란의 정리: 연구 투명성의 문제  이성욱 2014/07/10 1876
912   Stem cell treatment causes nasal growth in woman's back  이성욱 2014/07/09 1510
911   자폐증과 특이적 유전적 연결  이성욱 2014/07/08 1919
910   2가지 줄기세포 생성 방법(핵치환과 역분화)의 충실성(fidelity) 비교 결과: 승자는?  이성욱 2014/07/07 1703
909   STAP줄기세포논문 철회 결정  이성욱 2014/07/04 1453
908   새로운 감염에 의한 잠복 바이러스의 활성화  이성욱 2014/07/02 1642

[이전 10개] [1]..[11][12][13][14][15][16][17] 18 [19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN